Firms Tighten Tysabri Indication To Gain Panel Endorsement For Crohn’s

Given safety issues linked to Biogen Idec/Elan's Tysabri (natalizumab), the companies are narrowing the scope of the requested Crohn's disease indication from that initially proposed and studied in the clinical trials